0001209191-23-011566.txt : 20230222 0001209191-23-011566.hdr.sgml : 20230222 20230222145023 ACCESSION NUMBER: 0001209191-23-011566 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230217 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tananbaum James B. CENTRAL INDEX KEY: 0001581754 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39743 FILM NUMBER: 23652637 MAIL ADDRESS: STREET 1: 3052 PACIFIC AVENUE CITY: SAN FRANCISCO STATE: CA ZIP: 94115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kinnate Biopharma Inc. CENTRAL INDEX KEY: 0001797768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824566526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8582994699 MAIL ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-17 0 0001797768 Kinnate Biopharma Inc. KNTE 0001581754 Tananbaum James B. 900 LARKSPUR LANDING CIRCLE SUITE 150 LARKSPUR CA 94939 1 0 1 0 Common Stock 2023-02-17 4 J 0 1100000 A 1975001 I See Footnote Common Stock 9671643 I See Footnote Common Stock 291667 I See Footnote On February 17, 2023, the Issuer completed the acquisition of Kinnjiu Biompharma, Inc. (the "Kinnjiu Acquisition"). Foresite Capital Fund V, L.P. ("Fund V") was a shareholder of Kinnjiu Biompharma, Inc. and, as a result of the Kinnjiu Acquisition, Fund V received a combination of cash and 1,100,000 shares of the Issuer's Common Stock. Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757. The shares are owned directly by Fund V. Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. This Form 4 is one of two Form 4s filed on the date hereof in respect of these transactions. The Reporting Persons for the other Form 4 are Foresite Capital Management IV, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Management V, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. /s/ James B. Tananbaum 2023-02-22